An up-and-coming global biotechnology company was experiencing sustained, double-digit growth driven by expanding product portfolios and increasing global market presence. This growth translated directly into a rapid rise in drug safety case volumes and increasing regulatory complexity.
While the Pharmacovigilance, Risk Management, and Pharmacoepidemiology (PVRM) organization had evolved to meet immediate needs, its supporting IT systems, processes, and vendor relationships had developed incrementally over time. The result was a fragmented technology landscape that made it increasingly difficult to scale, adapt, and plan proactively.
The client recognized the need for a holistic, forward-looking IT strategy—one that aligned PVRM capabilities with broader enterprise IT investments while providing a resilient and flexible foundation to support continued growth.
The Challenge
- Rapid growth in safety case volume (>20% annually)
- Upcoming drug launches across Europe with increased regulatory demands
- Disparate and aging IT systems supporting PVRM operations
- Limited visibility into how current and future enterprise IT initiatives would impact pharmacovigilance
- A reactive approach to technology decisions, driven by immediate operational pressures rather than long-term strategy
Without intervention, these challenges risked slowing innovation, increasing operational risk, and constraining the organization’s ability to scale.
Ximpal Group partnered closely with senior PVRM and enterprise IT leadership to design a comprehensive IT strategy and execution roadmap grounded in both regulatory rigor and pragmatic implementation and setup the technology infrastructure to achieve their goals.
Our work focused on four integrated areas:
- Future-State Needs Assessment
We assessed current and emerging Pharmacovigilance, Risk Management, and Pharmacoepidemiology IT requirements, informed by regulatory trends, pipeline growth, and anticipated operational complexity. - Enterprise Alignment
We evaluated the broader enterprise IT strategy to identify dependencies, synergies, and constraints—ensuring PVRM investments were aligned with enterprise architecture, data strategy, and long-term technology direction. - Vendor Landscape Evaluation
We conducted a structured review of the existing vendor ecosystem, identifying gaps, redundancies, and opportunities to simplify and strengthen partnerships. - Strategy & Roadmap Development
Drawing on these inputs, we developed a holistic IT strategy and a realistic, three-year implementation roadmap. The roadmap balanced ambition with feasibility and clearly sequenced initiatives to minimize disruption while delivering near-term value.
The resulting strategy was presented to and formally endorsed by senior leadership, providing clear direction and organizational alignment.
Results & Impact
Ximpal Group’s IT Strategy and Roadmap enabled the client to transition from reactive problem-solving to proactive capability planning.
Key outcomes included:
- A clear, leadership-aligned vision for PVRM IT capabilities
- A practical three-year roadmap guiding investment and implementation decisions
- Improved readiness to support 20%+ annual growth in safety case volume
- Successful enablement of new drug launches in Europe
- Reduced operational risk through improved system coherence and planning
- Stronger alignment between PVRM needs and enterprise IT initiatives
Most importantly, the organization gained a scalable and flexible technology foundation capable of supporting continued growth, regulatory complexity, and future innovation.
The Value Delivered
This engagement exemplifies Ximpal Group’s ability to operate at the intersection of strategy, technology, and regulated operations. By combining deep domain understanding with disciplined planning and enterprise alignment, we helped our client build lasting capability—not just solve today’s problems.
The result was not simply a roadmap, but a strategic shift in how the organization plans for and invests in technology to support its mission.